Healthy, Muscle Disuse Atrophy
Conditions
Brief summary
There are times in life when people cannot use their muscles, such as during illness or injury. Muscle and mitochondria (the 'energy factory' in cells) health decline very quickly when people cannot use their muscles, but certain foods can help reduce these declines. Recent research suggests that Urolithin A, which is a natural compound that can be produced after eating pomegranates, nuts, and berries, improves muscle health. In this study, the investigators aim to investigate if a protein beverage (standard care during disuse) with or without Urolithin A can reduce or prevent the loss of muscle health while wearing a knee brace (muscle disuse).
Detailed description
After participants provide informed consent to participate and are deemed eligible for the study (Day 0), participants will sequentially complete the three phases of this study: 1. RUN-IN phase: participants continue habitual lifestyle (Day 7-Day 14 \[1 week\]) 2. IMMOBILIZATION phase: participants undergo 2 weeks of unilateral knee immobilization (Day 14-Day 28 \[2 weeks\]) 3. RECOVERY phase: participants return to habitual lifestyle (Day 28-Day 35 \[1 week\]) Participants will consume their randomly assigned supplement daily during all three phases.
Interventions
DIETARY_SUPPLEMENTProtein supplement
Ready-to-drink protein beverage consumed once daily for 28 days
DIETARY_SUPPLEMENTProtein supplement with Urolithin A
Ready-to-drink protein beverage with 1000 mg of Urolithin A consumed once daily for 28 days
Sponsors
McMaster University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
1. Men aged 18-30 years 2. Healthy, non-smoking 3. BMI between 20 and 30 kg/m\^2 4. No orthopedic issues that would preclude participation in the knee bracing protocol 5. Not taking any medication or with any medical condition that, in the opinion of the investigators, would compromise the study outcome or the safety of the research participant 6. Provide informed consent 7. Understand COVID-19 risks and procedures for in person research and sign Information Letter: COVID-19 Risks and Procedures for In-Person Research at McMaster University
Exclusion criteria
1. Subject has any concurrent medical, orthopedic, or psychiatric requirements that, in the opinion of the investigators, would compromise their ability to comply with the study requirements 2. Clinically significant abnormal laboratory results at screening 3. Participation in a clinical research trial within 30 days before randomization 4. Allergy or sensitivity to study ingredients 5. Individuals who are cognitively impaired and/or who are unable to give informed consent 6. Any other condition that, in the opinion of the investigators, may adversely affect the subject's ability to complete the study or its measures or may pose a significant risk to the subject 7. Any cachexia-related condition or any genetic muscle diseases or disorders 8. Current gastrointestinal condition that could interfere with the study (e.g., IBS/IBD \[irritable bowel syndrome/inflammatory bowel disease\], diarrhea, acid reflux disease, dysphagia, etc.) 9. Excessive alcohol consumption (\>21 units/week) and/or a smoker (cigarettes or vaping) 10. Concomitant use of corticosteroids, antibiotics, any anabolic steroid, creatine, whey protein supplements, casein, branched-chain amino acids (BCAAs) or any other NHP \[Natural Health Product\], medication or supplement used for muscle strengthening/building within 45 days prior to screening 11. Contraindications to an MRI scan (metal implants, metal-based ink tattoo)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in maximal mitochondrial respiration (rate of oxygen flux) and mitochondrial ADP [adenosine diphosphate] sensitivity (Oroboros O2k) | Outcome measured and reported for: Day 7, Day 14, Day 28, Day 35 | Oxygen flux in muscle measured using Oroboros |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Muscle strength (Biodex) | Day 7, Day 14, Day 28, Day 35 | Isometric leg extension strength |
| Quadriceps muscle size | Outcome measured and reported for: Day 14, Day 28, Day 35 | Muscle size measured using MRI |
| Muscle protein fractional synthetic rate | Day 7, Day 14, Day 28, Day 35; integrated synthesis rates reported for Day 7-14, Day 14-28; Day 28-35 | Protein synthetic rate using labelled alanine incorporation |
Countries
Canada
Outcome results
None listed